Anti -Myosin Light Chain 2 (MLC2, Myosin Regulatory Light Chain, MRLC, RLC, LC20)

For Research Use Only. Not for use in diagnostic procedures.

Chromosome: 12; NC_000012.11 (111348623..111358404, complement). Location: 12q24.11

Polyclonal

IgG

Rabbit

Detects endogenous levels of mouse total Myosin Light Chain 2. Species Crossreactivity: human, rat.

Affinity Purified
Purified by immunoaffinity chromatography.

Supplied as a liquid in PBS (without Mg2+ and Ca2+), pH 7.4, 0.02% sodium azide, 50% glycerol.

May be stored at 4 degree C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20 degree C. Aliquots are stable for at least 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

Small volumes of anti-MYL2 antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

The muscle myosins and hexomeric proteins consisting of two heavy chains and two pairs of light chains, the latter called essential (ELC) and regulatory (RLC). The light chains stabilize the long alpha helical neck of the myosin head. Human myosin light chain-2 (MYL2) is an important protein involved in the regulation of myosin ATPase activity in smooth muscle. In cardiac muscle, the precise role of MYL2 is not well understood; however, an increase in ventricular MYL2 is observed during myocardial hypertrophy in cardiac patients with valve stenosis. Familial hypertrophic cardiomyopathy (FHC) is an autosomal dominant disease caused by mutations in all of the major sarcomeric proteins, including the ventricular myosin regulatory light-chain (RLC). The Myosin RLC mutation has been associated with a rare variant of cardiac hypertrophy defined by mid-left ventricular obstruction due to papillary muscle hypertrophy. This mutation was later found to cause ventricular and septal hypertrophy.

Antibodies; Abs to Myosin

Western Blot (WB)

Suitable for use in Western Blot.
Dilution: Western Blot: 1:500-1:1,000

18,789 Da[Similar Products]

myosin, light chain 2, regulatory, cardiac, slow

myosin regulatory light chain 2, ventricular/cardiac muscle isoform; MLC-2; MLC-2v; RLC of myosin; myosin light chain 2; regulatory light chain of myosin; cardiac ventricular myosin light chain 2; slow cardiac myosin regulatory light chain 2; myosin, light polypeptide 2, regulatory, cardiac, slow

Myosin regulatory light chain 2, ventricular/cardiac muscle isoform

MLC-2; MLC-2v??[Similar Products]

MLRV_HUMAN

Thus gene encodes the regulatory light chain associated with cardiac myosin beta (or slow) heavy chain. Ca+ triggers the phosphorylation of regulatory light chain that in turn triggers contraction. Mutations in this gene are associated with mid-left ventricular chamber type hypertrophic cardiomyopathy. [provided by RefSeq, Jul 2008]

MRLC2V: myosin regulatory light chain 2, ventricular/cardiac muscle isoform. Ca+ triggers the phosphorylation of regulatory light chain that in turn triggers contraction. Mutations in MYL2 are associated with mid-left ventricular chamber type hypertrophic cardiomyopathy.

Protein type: Contractile

Chromosomal Location of Human Ortholog: 12q24.11

Cellular Component: sarcomere; cytoskeleton; myofibril; myosin complex; cytosol; A band; actin cytoskeleton

Molecular Function: actin monomer binding; protein binding; structural constituent of muscle; calcium ion binding; myosin heavy chain binding

Biological Process: muscle cell fate specification; heart contraction; regulation of striated muscle contraction; ventricular cardiac muscle morphogenesis; cardiac myofibril assembly; negative regulation of cell growth; muscle fiber development; muscle filament sliding; post-embryonic development; cardiac muscle contraction

Disease: Cardiomyopathy, Familial Hypertrophic, 10

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.